# Who does LigaChem Biosciences pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/ligachem-biosciences · Facet: suppliers · Updated: 2026-09-04T23:10:43.505657+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: LigaChem Biosciences's confirmed suppliers/cost counterparties include 삼성바이오로직스 (ADC CDO·CMO 위탁개발·생산) plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 3 cost edges, backed by 3 dated sources, 1 of them primary filings (as of 2026-09-04).

### 자체 연구개발비 (ADC 파이프라인 R&D) (high)
- metric: Amount ₩217.1B · 연구개발비용 계(연결)
- note: FY2025 R&D spend of KRW 217.1bn (~153.4% of revenue); candidate discovery and clinical trials for out-licensing are the main cost driver.
- [confirms] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "R&D expense total KRW 217,097,516 thousand; R&D-to-revenue ratio 153.37%."

### 삼성바이오로직스 (ADC CDO·CMO 위탁개발·생산) (high)  → /samsung-biologics.md
- note: Signed a CDO agreement with Samsung Biologics in Feb 2024 and a material-transfer agreement in Jun 2024; ADC development and manufacturing run at Samsung's dedicated ADC facility in Songdo (3+ projects in 2025).
- [mentions] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "The company relies on qualified CMOs to produce candidate drug samples."
- [confirms] Edaily Pharm (KO, news, published 2024-06-17) https://pharm.edaily.co.kr/news/read?newsId=03722806642038048: "Samsung Biologics and LigaChem signed a CDO deal in Feb 2024 and an MTA in Jun 2024 to collaborate on ADC development and manufacturing."

### 익수다 테라퓨틱스(Iksuda Therapeutics) (mid)
- metric: Market share 77.14% · 지배력 획득 최대 지분
- note: Acquired control of UK-based Iksuda Therapeutics (a longtime ADC platform licensee) on 31 Mar 2025 via forward and put arrangements, taking up to 77.14% and consolidating it as a subsidiary.
- [confirms] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "Secured up to 77.14% of Iksuda and gained control on 31 Mar 2025, consolidating it as a subsidiary."

### 항체 기술도입 파트너 (Mediterranea·Elthera·와이바이오 등) (mid)
- note: In-licenses target antibodies for its ADCs from multiple partners: the LCB84 Trop2 antibody from Mediterranea Theranostic, plus antibody deals with Elthera (Switzerland, Feb 2023), Daan Bio, Y-Biologics, Novarock and Go Therapeutics.
- [confirms] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "Feb 2023 antibody in-license from Elthera (Switzerland); in 2025 antibody deals with Daan Bio, Y-Biologics, Novarock and Go Therapeutics."
- [confirms] Business Wire (EN, news, published 2023-12-25) https://www.businesswire.com/news/home/20231225841872/en/: "LCB84's Trop2 antibody is licensed from Mediterranea Theranostic, S.r.l."

Reverse side: https://valuechain.wiki/ligachem-biosciences/customers.md · Ripple: https://valuechain.wiki/ligachem-biosciences/ripple.md

---
Full node: https://valuechain.wiki/ligachem-biosciences.md · JSON: https://valuechain.wiki/ligachem-biosciences.json